0.01
0.00%
Close of 27 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Trevena
Its shares trade under the ticker TRVN. It has been listed since 31 January 2014. In the fiscal year to 31 December 2023, it reported revenue of $3.1m and a net loss of $40.3m. At that date it held total assets of $40.6m and shareholders' equity of −$7.7m.
Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. The company is headquartered in Chesterbrook, Pennsylvania. The company went IPO on 2014-01-31. The firm is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. The company is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. The company is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. The company is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 31 Jan 2014
- Employees
- 24
- Website
- trevena.com ↗
Leadership
Pay as last reported
- Ms. Carrie BourdowChairman of the Board, Acting Chief Executive Officer, since 2015$1.7m
- Ms. Katrine SuttonPrincipal Financial Officer
- Mr. Barry ShinChief Operating Officer$1.0m
- Ms. Patricia DrakeSenior Vice President and Chief Commercial Officer
- Mr. Robert YoderSenior Vice President, Chief Business Officer and Head - Commercial Operations$689,161
- Dr. Mark DemitrackActing Chief Medical Officer$1.0m
- Ms. Barbara YanniIndependent Director$76,576
- Mr. Dan FerryManaging Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 60
- Environment
- 67
- Social
- 50
- Governance
- 63
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Trevena Inc develops OLINVO for acute pain management in hospitals and surgery centers.
- Trevena Inc focuses on TRV250 for migraine treatment with non-narcotic mechanism.
- Trevena Inc utilizes ABLE platform for GPCR-targeted biased ligands research.
Weaknesses
- Trevena Inc has only 24 employees for biotechnology development.
- Trevena Inc's IPO was in 2014, showing limited market presence.
- Trevena Inc is developing products in early stages without commercial sales.
Opportunities
- Trevena Inc can expand OLINVO use in acute care settings across the US.
- Trevena Inc may explore TRV250 for other CNS indications beyond migraine.
- Trevena Inc could leverage UK Phase I study for TRV250 to enter European markets.
Threats
- Trevena Inc faces competition from established biotech firms in CNS disorders.
- Trevena Inc's early-stage products risk clinical trial failures.
- Trevena Inc depends on successful FDA approval for OLINVO and TRV250.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.